Loading organizations...
§ Private Profile · Irvine, CA, USA
Medical device manufacturer developing electrophysiology catheters for cardiologists treating cardiac arrhythmias.
Key people at Biosense Webster.
Biosense Webster is an Irvine, California-based medical device manufacturer that designs and produces advanced electrophysiology products for the diagnosis and treatment of cardiac arrhythmias. Operating as a major subsidiary of Johnson & Johnson MedTech, the company contributes significantly to an Interventional Solutions segment that generated over $6.3 billion in global revenue during 2023. The enterprise supplies hospitals and clinical electrophysiologists worldwide with capital medical equipment and high-margin single-use consumables, employing thousands of workers across its international manufacturing operations. Under the leadership of President Jasmina Brooks, the organization develops prominent cardiovascular technologies including the CARTO 3 Mapping System, THERMOCOOL ablation catheters, and the VARIPULSE platform. The current corporate entity was established in 1998 through the merger of two acquired businesses originally founded by Shlomo Ben-Haim, Amit Ben-Haim, and Wilton Wells Webster Jr.
Key people at Biosense Webster.
Biosense Webster is a global leader in developing advanced medical technologies for diagnosing and treating heart rhythm disorders, particularly through electrophysiology. The company builds innovative products such as the CARTO® 3 System, a real-time, three-dimensional cardiac mapping and navigation platform, and therapeutic ablation catheters like the NAVISTAR® THERMOCOOL® Catheter. These products serve electrophysiologists and hospitals worldwide by improving the accuracy, speed, and safety of cardiac arrhythmia treatments, addressing critical unmet patient needs. Biosense Webster has demonstrated strong growth momentum through continuous innovation and strategic collaborations with major imaging companies, reinforcing its leadership in cardiac electrophysiology[1][3].
Founded in 1999 and headquartered in Diamond Bar, California, Biosense Webster originated from the pioneering work of Wilton "Will" W. Webster Jr., a mechanical engineer who developed the first steerable tip catheter with an effective radiofrequency (RF) electrode. His early collaboration with physicians to create customized catheters for diagnosing and curing arrhythmias like Wolf-Parkinson-White Syndrome laid the foundation for the company’s success. The company’s breakthrough came with the introduction of the world’s first 3D cardiac mapping system in 1995 and the first irrigated ablation catheter in 1998, which significantly advanced electrophysiology procedures[1][2].
Biosense Webster rides the trend of precision medicine and minimally invasive cardiac care, leveraging advances in imaging, navigation, and catheter technology. The timing is critical as the global burden of cardiac arrhythmias grows with aging populations, increasing demand for effective, less invasive treatments. Market forces such as rising healthcare investments in cardiovascular innovation and the push for integrated diagnostic and therapeutic platforms favor Biosense Webster’s comprehensive solutions. The company influences the broader ecosystem by setting technological benchmarks and fostering collaborations that accelerate adoption of advanced electrophysiology tools[1][3].
Looking ahead, Biosense Webster is poised to expand its impact through further integration of imaging, AI, and data analytics to enhance procedural outcomes and patient safety. Trends such as personalized cardiac care, remote monitoring, and hybrid operating rooms will shape its product evolution. Its influence is likely to grow as it continues to lead innovation and partnerships, maintaining its role as a cornerstone in cardiac electrophysiology and contributing to improved global cardiovascular health[1][3].
